BRCA突变状态、初始疾病表现与高级别浆液性晚期卵巢癌临床结局:一项多中心研究
该回顾性多中心研究纳入273例新诊断FIGO IIIC-IV期高级别浆液性卵巢癌患者,BRCA1/2胚系突变者107例(39.2%)。突变者腹膜播散无卵巢肿块(25.2% vs 13.9%,P=.018)、大块淋巴结(30.8% vs 17.5%,P=.010)及腹腔镜预测指数≥8(42.1% vs 27.1%,P=.016)比例更高。BRCA野生型者初次减灭术较新辅助化疗中位无进展生存延长8个月(26 vs 18个月,P=.003)。
要点
- BRCA1/2胚系突变者诊断时腹膜肿瘤负荷更高、大块淋巴结更常见。
- BRCA野生型者初次减灭术较新辅助化疗中位无进展生存延长8个月(26 vs 18个月,P=.003)。
- BRCA突变状态可能有助于个体化治疗决策。
核心结论
- BRCA1/2突变女性诊断时腹膜肿瘤负荷更高、大块淋巴结频率增加。
- BRCA野生型基因型女性中,初次减灭术似乎较新辅助化疗确保更长的无进展生存。
- BRCA检测可能是高级别浆液性卵巢癌个体化治疗的可靠工具。
研究设计与样本
- 回顾性多中心研究,纳入连续新诊断FIGO IIIC-IV期高级别浆液性卵巢癌患者,随访至少18个月并检测BRCA1/2胚系突变状态。
- 324例患者接受BRCA检测,273例符合纳入标准。
主要发现
- 107例(39.2%)存在BRCA1/2胚系突变。
- BRCA突变状态在FIGO分期、CA125水平或腹水存在方面无差异。
- BRCA1/2突变者腹膜播散无卵巢肿块发生率25.2% vs 野生型13.9%(P=.018)。
- BRCA1/2突变者大块淋巴结发生率30.8% vs 野生型17.5%(P=.010)。
- BRCA1/2突变者腹腔镜预测指数≥8比例42.1% vs 野生型27.1%(P=.016)。
关键数值与推荐
- BRCA1/2突变组中,初次减灭术与新辅助化疗中位无进展生存无差异(P=.268)。
- BRCA野生型组中,初次减灭术后中位无进展生存26个月 vs 新辅助化疗18个月(P=.003)。
- 无进展生存定义为从初始诊断(分期腹腔镜)至复发或末次随访的月数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the last decades, there have been several efforts to clarify the role of BRCA mutational status in women with advanced ovarian cancer, demonstrating its role in cancer development, as well as the prognostic significance of BRCA genotype. OBJECTIVE: Our aim is to evaluate the correlation between BRCA mutational status and disease presentation in a large series of advanced high-grade serous ovarian cancer patients. STUDY DESIGN: This is a retrospective multicenter study including a consecutive series of newly diagnosed high-grade serous ovarian cancer patients with International Federation of Gynecology and Obstetrics stage IIIC-IV disease, at least 18 months of follow-up time, and tested for BRCA 1/2 germline mutation status. Disease presentation was analyzed using the following variables: laparoscopic predictive index value, incidence of bulky lymph nodes, and ovarian masses. Progression-free survival was defined as the months elapsed from initial diagnosis (staging laparoscopy) and recurrent disease or last follow-up. RESULTS: In all, 324 high-grade serous ovarian cancer patients received BRCA testing, and 273 fulfilled inclusion criteria. BRCA1/2 germline mutations were observed in 107 women (39.2%). No differences were documented according to BRCA mutation status in terms of International Federation of Gynecology and Obstetrics stage, CA125 levels, or presence of ascites. In patients with BRCA1/2 mutations we observed a higher incidence of peritoneal spread without ovarian mass (25.2% vs 13.9%; P value = .018) and of bulky lymph nodes (30.8% vs 17.5%; P value = .010) compared with women showing BRCA1/2 wild type genotype. Furthermore, women with BRCA1/2 mutations showed high peritoneal tumor load (laparoscopic predictive index value ≥8; 42.1% vs 27.1%; P value = .016) more frequently. Focusing on survival, no differences in term of median progression-free survival were observed among women treated with primary debulking surgery and neoadjuvant chemotherapy in the group of patients with BRCA1/2 mutations (P value = .268). On the other hand, in women showing BRCA wild type genotype, median progression-free survival after primary debulking surgery was 8 months longer compared with patients treated with neoadjuvant chemotherapy approach (26 vs 18 months; P value = .003). CONCLUSION: Women with BRCA1/2 mutations show at diagnosis higher peritoneal tumor load and increased frequency of bulky lymph nodes compared to patients without germline BRCA mutations. Primary debulking surgery seems to ensure a longer progression-free survival in women with BRCA wild type genotype compared to neoadjuvant chemotherapy. BRCA testing might be a reliable tool to personalize treatment in patients with high-grade serous ovarian cancer, thus giving novel points of discussion to the ongoing debate regarding the best initial treatment approach.
引用
- Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017. PMID: 28549976. doi:10.1016/j.ajog.2017.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。